Merck’s TROP2 ADC extends survival in pivotal gastroesophageal cancer trial

Merck & Co. headquarters
Merck hailed the gastroesophageal adenocarcinoma readout as a first for a TROP2-directed ADC. (Merck & Co.)

Merck & Co.’s sacituzumab tirumotecan (sac-TMT) has improved overall survival (OS) in a phase 3 cancer trial, delivering a second pivotal global victory for the Kelun Biotech-partnered TROP2-directed antibody-drug conjugate (ADC).

The study, TroFuse-015, enrolled 473 people with advanced unresectable or metastatic gastroesophageal adenocarcinoma who received at least two prior lines of systemic therapy. Participants received sac-TMT—which is approved in China—or the treatment physician’s choice (TPC), consisting of trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel.

At the final analysis, OS was significantly longer on sac-TMT than on TPC, achieving the trial’s primary endpoint. Results were generally consistent across subgroups regardless of TROP2 expression status, Merck said.

Sac-TMT improved OS despite failing to show a statistically significant effect on progression-free survival, a secondary endpoint. The FDA recommends that sponsors prioritize OS as the primary endpoint when feasible, calling (PDF) it the gold standard. Sac-TMT had a nominal effect on objective response rate, but Merck didn’t formally test that efficacy measure under its prespecified analysis plan.  

Merck hailed the readout, which was free from safety surprises, as the first time a TROP2-directed ADC has improved OS compared with TPC in this patient population in a global phase 3 study. The drugmaker achieved that landmark despite trailing rivals in the wider TROP2 race. 

The FDA approved Trodelvy, which Gilead now owns, in 2020. AstraZeneca and Daiichi Sankyo won FDA approval for Datroway in 2025. Trodelvy and Datroway are approved in breast cancer, while Datroway’s label also includes a non-small cell lung cancer population. 

Merck’s TroFuse R&D program, which features 18 phase 3 trials, covers breast and lung cancer alongside tumor types that its rivals have yet to unlock. The program includes 14 first-in-class opportunities. Merck delivered its first global phase 3 win in May, reporting that the TroFuse-005 endometrial cancer study met its primary endpoints. 

The second win arrived ahead of schedule. In an August note to investors, Guggenheim Securities analysts said they expected Merck to report results in the first half of 2027. The forecast reflected the estimated primary completion date of January 2027, when TroFuse-015 actually reached primary completion last month.